AYTU BioPharma
AYTU
27 hedge funds and large institutions have $5.46M invested in AYTU BioPharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
23% more funds holding
Funds holding: 22 → 27 (+5)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
9% more capital invested
Capital invested by funds: $5.03M → $5.46M (+$429K)
0.44% more ownership
Funds ownership: 31.79% → 32.23% (+0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$43.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.8K |
| 3 |
Renaissance Technologies
New York
|
+$6.87K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.34K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$17.8K |
| 2 |
Morgan Stanley
New York
|
-$4.98K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.55K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$20 |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$11 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| $6 | +$3 | +1 | +100% |
|
27
Citigroup
New York
| – | -$3 | -1 | Closed |
|
AYTU Hedge Fund Activity: Q1 2024 in Review
27 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2024, worth a combined $5.46M — up 8.5% from $5.03M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AYTU positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $43.6K. The largest seller was JP Morgan Chase, cutting an estimated $17.8K.
- 27 institutional investors held AYTU BioPharma (AYTU) as of Q1 2024, up from 22 in Q4 2023.
- Funds reported $5.46M of AYTU BioPharma stock for Q1 2024, up 8.5% quarter-over-quarter.
- 6 funds opened new AYTU BioPharma positions in Q1 2024 and 1 closed out, a net change of +5 holders.
- The largest AYTU BioPharma buyer in Q1 2024 was Dimensional Fund Advisors, an estimated $43.6K added.
- The largest AYTU BioPharma seller in Q1 2024 was JP Morgan Chase, an estimated $17.8K sold.
Based on aggregated 13F filings for Q1 2024.